Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa

References

• Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-94
   PubMed Web of Science ®Google Scholar
• The Centers for Disease Control and Prevention: Hemophilia Data and Statistics. http://www.cdc.gov/ncbddd/hemophilia/data.html. Updated in 2010
   Google Scholar
• Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.[see comment]. Lancet 1992;339:594-8
   PubMed Web of Science ®Google Scholar
• Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.[see comment]. Thromb Haemost 1998;79:762-6
   PubMed Web of Science ®Google Scholar
• DiMichele DM. Inhibitors in haemophilia: a primer. Haemophilia 2000;6(Suppl 1):38-40
   PubMedGoogle Scholar
• Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009;113:11-17
   PubMed Web of Science ®Google Scholar
• Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983;61:36-40
   PubMed Web of Science ®Google Scholar
• Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997;77:1113-19
   PubMed Web of Science ®Google Scholar
• Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-18
   PubMed Web of Science ®Google Scholar
• Iorio A, Matino D, D’Amico R, et al. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley, 2010
   Google Scholar
• Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007;109:546-51
   PubMed Web of Science ®Google Scholar
• Stephens JM, Joshi AV, Sumner M, et al. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opin Pharmacother 2007;8:1127-36
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007;25:1007-29
   PubMed Web of Science ®Google Scholar
• Knight C, Dano AM, Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia 2009;15:405-19
   PubMed Web of Science ®Google Scholar
• Huth-Kuehne A, Lages P, Zimmermann R. The impact of rebleeds in cost modelling of treatment strategies in patients with hemophilia A and inhibitors. ASH Annual Meeting Abstracts 2006;108:4046
   Google Scholar
• Knight C, Paisley S, Wight J, et al. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003;9:521-40
   PubMed Web of Science ®Google Scholar
• Ekert H, Brewin T, Boey W, et al. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001;7:279-85
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer price index - Medical care services. Available at http://data.bls.gov/cgi-bin/surveymost. Accessed July 10, 2010
   Google Scholar
• Odeyemi I, Guest J. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UK. J Med Econ 2002;5:119-33
   Google Scholar
• Odeyemi I, Guest J. Modelling the economic impact of recombinant activated factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX at a comprehensive care centre in the UK. J Med Econ 2002;5:61-4
   Google Scholar
• Chung K, Berger A, Edelsberg J, Neufeld E, et al. Cost-effectiveness of FEIBA for the treatment of mildto-moderate bleeds in hemophilia patients with inhibitors. Abstracts of the XXVIth International Congress of The World Federation of Hemophilia. Haemophilia 2004;10:29-33
   Google Scholar
• Putnam KG, Bohn RL, Ewenstein BM, et al. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors.[see comment]. Haemophilia 2005;11:261-9
   PubMed Web of Science ®Google Scholar
• Dundar S, Zulfikar B, Kavakli K, et al. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ 2005;8:45-54
   Google Scholar
• Joshi AV, Stephens JM, Munro V, et al. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin 2006;22:23-31
   PubMed Web of Science ®Google Scholar
• Ozelo MC, Villaca PR, De Almeida JO, et al. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007;13:462-9
   PubMedGoogle Scholar
• Steen Carlsson K, Astermark J, Donfield S, et al. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008;99:1060-7
   PubMedGoogle Scholar
• You CW, Lee SY, Park SK. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea. Haemophilia 2009;15:217-26
   PubMedGoogle Scholar
• Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007;13:256-63
   PubMed Web of Science ®Google Scholar
• Hilgartner M, Aledort L, Andes A, et al. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990;30:626-30
   Google Scholar
• Seremetis S, Joshi AV, Asmussen M. Cost minimization model for treatment of minor bleeding episodes in inhibitor patients – methodological issues.[comment]. Haemophilia 2006;12:108-9
   PubMedGoogle Scholar
• Donfield SM, Astermark J, Lail AE, et al. Value added: increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008;14:276-80
   PubMedGoogle Scholar
• Hay JW, Zhou ZY. Commentary on Knight, et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia 2010;16:366-8; discussion 9-71
   PubMedGoogle Scholar
• Hay JW, Zhou ZY, Young G. Economic comparison of aPCC vs rFVIIa for mild-to-moderate bleeding episodes in hemophilia patients with inhibitors. Abstract of the XXII Congress of the International Society on Thrombosis and Haemostasis 2009
   Google Scholar
• Klintman J, Berntorp E, Astermark J. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia 2010;16:e210-15
   Google Scholar